## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.7% below STRENGTH zone (4.0-10.0%); PEG 6.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($376.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Mackenzie Financial Corp Purchases 96,506 Shares of Waters Corporation $WAT**
- Source: MarketBeat | 20251201T033814 | Bullish | Relevance: 97%
- Mackenzie Financial Corp significantly increased its stake in Waters Corporation (NYSE:WAT) during the second quarter, purchasing 96,506 additional shares to reach a total of 206,670 shares valued at approximately $72.14 million. Waters Corporation, a medical instruments supplier, currently holds an average analyst rating of "Moderate Buy" with a target price of $381.57. The company demonstrates strong profitability and trades with a market capitalization of $24.02 billion.

**2. Thermo Fisher Scientific (TMO) Stock on 1 December 2025: HSBC Upgrade, Insider Moves, Buyback and 2026â€“2030 Forecasts**
- Source: ts2.tech | 20251201T190803 | Neutral | Relevance: 64%
- This article analyzes Thermo Fisher Scientific (TMO) stock as of December 1, 2025, detailing an HSBC upgrade to "Buy," recent insider transactions, institutional investor moves, and a $5 billion share repurchase authorization. It also covers the company's Q3 2025 earnings beat, the strategic acquisition of Clario, and various analyst and algorithmic forecasts for its future performance through 2030. The piece concludes with a balanced view of the bullish and cautionary factors for TMO stock.

**3. A Fresh Look at Cooper Companies (COO) Valuation Following Activist Push for Strategic Overhaul**
- Source: Simply Wall Street | 20251129T143540 | Neutral | Relevance: 55%
- Cooper Companies (COO) has garnered market attention after an activist investor pushed for significant changes. Despite a recent surge in share price, the company's valuation remains under scrutiny, with different analyses presenting it as either undervalued or potentially overpriced compared to industry averages due to its high price-to-earnings ratio. The focus is on whether recent strategic moves and product rollouts will justify its current market excitement.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wolfe Research | $48 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wolfe Research | up | Outperform |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Share repurchase program provides demand floor and EPS support.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 6.42 signals overvaluation risk, limited margin of safety. Forward P/E 27.8x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.6B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.42 |
| Forward P/E | 27.8 |
| Current P/E | 30.3 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 8.8% to 2.7% (-6.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.3pp (needs >4.0% for momentum thesis). MRS_5 (-2.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.9% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.62), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.73% (CS: 78) | Neutral |
| RSI_14 | 65.7 | Neutral |
| MACD Histogram | 0.62 | Bullish |
| vs SMA20 | 1.039x | Above |
| vs SMA50 | 1.137x | Above |
| vs SMA200 | 1.175x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $397.79
- **Stop Loss:** $376.47 (5.4% risk)
- **Target:** $419.11 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 35
- **Position Value:** $13,922.65
- **Portfolio %:** 13.92%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*